We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib
Read MoreHide Full Article
Incyte Corporation (INCY - Free Report) and Eli Lilly and Company (LLY - Free Report) provided updates from two phase III studies, RA-BEAM and RA-BUILD, on baricitinib for the treatment of rheumatoid arthritis (RA).
RA-BEAM evaluated baricitinib, in comparison to AbbVie Inc.’s (ABBV - Free Report) Humira, in patients who had active moderate-to-severe RA, despite ongoing treatment with methotrexate. RA-BUILD, on the other hand, evaluated the candidate, in comparison to placebo, in patients with moderate-to-severe RA who previously had an inadequate response to, or were intolerant of, at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD) and had not received a biologic DMARD.
Findings from both the studies demonstrated that patients on the baricitinib (4 mg) arm experienced significant improvements in joint pain, severity of morning joint stiffness and tiredness, compared to both placebo and Humira.
Results were presented at an annual meeting of the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP).
In a separate press release, Incyte and Eli Lilly announced new data analyses from the same studies. Data from three post-hoc analyses on baricitinib showed improvements in RA symptoms in patients irrespective of age, body mass index (BMI) and previous treatments with csDMARDs.
We note that in Jan 2016, Eli Lilly submitted a regulatory application for baricitinib in both the U.S. and the EU for the treatment of patients with mild-to-moderate severe RA. As per a WHO Global Burden of Disease Report, over 23 million people suffer from RA across the world.
Meanwhile, baricitinib is being evaluated in phase IIa study for the treatment of atopic dermatitis and in a phase II study for the treatment of systemic lupus erythematosus.
Incyte is a Zacks Rank #2 (Buy) stock, while Eli Lilly carries a Zacks Rank #3 (Hold). Cambrex Corp. is a top-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates have increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the trailing four quarters with an average beat of 19.78%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib
Incyte Corporation (INCY - Free Report) and Eli Lilly and Company (LLY - Free Report) provided updates from two phase III studies, RA-BEAM and RA-BUILD, on baricitinib for the treatment of rheumatoid arthritis (RA).
RA-BEAM evaluated baricitinib, in comparison to AbbVie Inc.’s (ABBV - Free Report) Humira, in patients who had active moderate-to-severe RA, despite ongoing treatment with methotrexate. RA-BUILD, on the other hand, evaluated the candidate, in comparison to placebo, in patients with moderate-to-severe RA who previously had an inadequate response to, or were intolerant of, at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD) and had not received a biologic DMARD.
Findings from both the studies demonstrated that patients on the baricitinib (4 mg) arm experienced significant improvements in joint pain, severity of morning joint stiffness and tiredness, compared to both placebo and Humira.
Results were presented at an annual meeting of the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP).
INCYTE CORP Price
INCYTE CORP Price | INCYTE CORP Quote
In a separate press release, Incyte and Eli Lilly announced new data analyses from the same studies. Data from three post-hoc analyses on baricitinib showed improvements in RA symptoms in patients irrespective of age, body mass index (BMI) and previous treatments with csDMARDs.
We note that in Jan 2016, Eli Lilly submitted a regulatory application for baricitinib in both the U.S. and the EU for the treatment of patients with mild-to-moderate severe RA. As per a WHO Global Burden of Disease Report, over 23 million people suffer from RA across the world.
Meanwhile, baricitinib is being evaluated in phase IIa study for the treatment of atopic dermatitis and in a phase II study for the treatment of systemic lupus erythematosus.
LILLY ELI & CO Price
LILLY ELI & CO Price | LILLY ELI & CO Quote
Zacks Rank & Key Picks
Incyte is a Zacks Rank #2 (Buy) stock, while Eli Lilly carries a Zacks Rank #3 (Hold). Cambrex Corp. is a top-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates have increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the trailing four quarters with an average beat of 19.78%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>